A Dark Vector Cognition product

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

68K characters. Original on sec.gov ·

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The 23 tables in Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements and related notes of this Quarterly Report on Form 10-Q and our audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for fiscal year 2025 as filed with the SEC on February 18, 2026. The following discussion contains forward-looking statements. Actual results may differ significantly from those projected in the forward-looking statements. Factors that might cause future results to differ materially from those projected in the forward-looking statements include, but are not limited to, those discussed in Item 1A, “Risk Factors” included elsewhere within this Form 10-Q. Certain percentage changes may not recalculate due to rounding.

Overview

We are a leading, full service, non-clinical global drug development partner. For over 75 years, we have been in the business of providing the research models required in the research and development of new drugs, devices, and therapies. Over this time, we have built upon our original core competency of laboratory animal medicine and science (research model technologies) to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, that supports our clients from target identification through non-clinical development. We also provide a suite of products and services to support our clients’ manufacturing activities. Utilizing our broad portfolio of products and services enables our clients to create a more efficient and flexible drug development model, which reduces their costs, enhances their productivity and effectiveness, and increases speed to market.

Our client base includes major global pharmaceutical companies; many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world.

Segment Reporting

Our three reportable segments are Discovery and Safety Assessment (DSA), Manufacturing Solutions (Manufacturing), and Research Models and Services (RMS).

Our DSA segment is comprised of Discovery and Safety Assessment services. We provide regulated and non-regulated DSA services to support the discovery, development, and regulatory-required safety testing of potential new drugs, including in vitro (non-animal), in vivo (in research models) and in silico studies, laboratory support services, including bioanalytical and strategic non-clinical consulting and program management to support product development. In May 2026, we sold certain European Discovery Services businesses.

Our Manufacturing reportable segment includes Microbial Solutions, which provides in vitro lot-release testing products, microbial detection products, and species identification services and Biologics Testing (Biologics), which performs specialized testing of biologics. In May 2026, we sold the contract development and manufacturing products and services (CDMO) business, reported in the Manufacturing segment.

Our RMS reportable segment includes the products and services offered within Research Models, Research Model Services, and Cell Solutions. Research Models includes the commercial production and sale of small research models, as well as the supply of large research models. Research Model Services includes: Insourcing Solutions (IS), which provides colony management of our clients’ research operations (including recruitment, training, staffing, and management services) within our clients’ facilities as well as our own vivarium space, utilizing our Charles River Accelerator and Development Lab (CRADL™) offerings, Genetically Engineered Models and Services (GEMS), which performs contract breeding and other services associated with genetically engineered models; and Research Animal Diagnostic Services (RADS), which provides health monitoring and diagnostics services related to research models. In May 2026, we sold the Cell Solutions business, reported in the RMS segment, which provided controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood and bone marrow as well as cells from disease state donors.

Fiscal Quarters

Our fiscal year is typically based on 52 weeks, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31. A 53rd week in the fourth quarter of the fiscal year is occasionally necessary to align with a December 31 calendar year-end.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Global Market Environment

We are continuing to see an improved spending environment from our client base, principally within our DSA segment, as the demand conditions have improved from levels experienced in the recent quarters, due primarily to increased biotech funding and global biopharmaceutical companies refocusing their investments on their early-stage research and development pipelines. Consistent with the improving demand environment, DSA backlog increased slightly to $2.0 billion as of September 26, 2026 from $1.9 billion as of December 27, 2025.

Strategic Vision and Restructuring Programs

We continuously assess opportunities to drive greater efficiencies through process improvements, cost-savings initiatives, and restructuring actions. During the third quarter of fiscal 2026, we announced our Create the Future program, which formalizes and expands the Company’s ongoing transformation and efficiency initiatives under a unified operating framework. Create the Future builds upon actions already underway, including process improvements, procurement synergies, global business service expansion, workforce optimization, and real estate footprint rationalization, while introducing additional initiatives focused on AI-enabled automation, simplification and digitization, and enterprise optimization.

Through the ongoing actions, the Company expects to achieve approximately $300 million of cumulative annualized cost savings by the end of 2026, with more than $175 million realized through fiscal 2025. In addition, the Create the Future program is expected to generate incremental cost savings in excess of $300 million between 2027 and 2030. Workforce-related actions have primarily resulted in severance and transition costs, while facility optimization activities have resulted in asset impairment charges, accelerated depreciation, and other site-related costs. Restructuring charges were $19.2 million and $73.8 million during the three and nine months ended September 26, 2026, respectively, compared with $99.8 million and $107.0 million in fiscal 2025 and 2024, respectively. For further details of these costs, see Note 15 – Restructuring and Asset Impairments in Part I, Item 1.

Recent Acquisitions

We make strategic acquisitions designed to expand our portfolio of products and services to support the drug discovery and development continuum. We maintain an acquisition strategy that focuses on augmenting internal growth of existing businesses with complementary acquisitions. Our recent transactions are described below.

On April 17, 2026, we completed the acquisition of an additional 79% equity interest in PathoQuest SAS (PathoQuest), for $67.4 million. The acquisition was funded through a combination of available cash and proceeds from the Credit Facility. This business is reported as part of our Manufacturing reportable segment. For more details, please see Note 2 – Acquisitions and Divestitures in Part I, Item 1.

On January 14, 2026, we completed the acquisition of certain assets of K.F. Cambodia Ltd (Cambodian NHP Supplier), a leading supplier of non-human primates (NHPs) located in Cambodia. The preliminary purchase price for the Cambodian NHP Supplier was $507.3 million, consisting of $335.0 million paid at closing and $172.3 million representing the acquisition date fair value of deferred consideration, which is payable upon the satisfaction of certain post-close conditions. During the three and nine months ended September 26, 2026, the Company paid $100.0 million and $170.0 million of deferred consideration, respectively, with the remaining balance of $5 million to be paid as of September 26, 2026. The acquisition was funded through a combination of available cash and proceeds from our Credit Facility. This business is reported as part of our DSA reportable segment for NHPs vertically integrated into the DSA supply chain and the RMS reportable segment for those NHPs sold to third party customers. For more details, please see Note 2 – Acquisitions and Divestitures in Part I, Item 1.

Recent Divestitures

We routinely evaluate the strategic fit and fundamental performance of our global businesses, divesting operations that do not meet key business criteria. As part of this ongoing assessment, we determined that certain capital could be better deployed in other long-term growth opportunities.

On May 22, 2026, we sold certain European Discovery Services businesses (European Discovery Divestiture) to IQVIA Inc. (IQVIA) for a purchase price of $126.4 million in cash, net of costs to sell and subject to certain customary closing adjustments. We may also earn up to $10.0 million of contingent payments, which are tied to future performance. The contingent payments have been valued at $2.8 million using a discounted probability weighted model. The results of the European Discovery Services businesses were reported in our DSA reportable segment. During the three and nine months ended September 26, 2026, we recorded a pre-tax gain on the divestiture of $1.1 million and $1.4 million, respectively, within Other expense, net on the unaudited condensed consolidated statements of income.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

On May 6, 2026, we sold our CDMO and Cell Solutions businesses (CDMO and Cell Solutions Divestiture) to GI Partners (GI) for net cash paid to the buyer of $12.4 million, net of costs to sell and subject to certain customary closing adjustments. Additionally, we may be required to fund up to $45.0 million of future EBITDA losses and capital expenditures of the divested businesses over a four-year period, which is expected to be fully used by GI. Conversely, we may also earn up to $50.0 million of contingent payments, which are tied to future performance and achievement of milestones. The contingent payments receivable have been valued at $15.7 million using a discounted probability weighted model. The results of the CDMO and Cell Solutions businesses were reported in our Manufacturing reportable segment and RMS reportable segment, respectively. These businesses and the related assets and liabilities met the criteria for held-for-sale as of March 28, 2026, resulting in a pre-tax loss of $118.0 million recognized for the three months ended March 28, 2026, which represents the excess of its carrying value over the fair value less cost to sell. Upon closing of the sale, a $63.7 million pre-tax loss on divestiture was recognized for the three months ended June 27, 2026. No pre-tax loss was recognized on the divestiture for the three months ended September 26, 2026. We recognized the pre-tax loss on divestiture of $181.7 million for the nine months ended September 26, 2026 within Other expense, net on the unaudited condensed consolidated statements of income.

In March 2026, we completed the sale of certain assets located at our Wilmington, Massachusetts site. The assets consisted of office, laboratory and mixed-use buildings within our RMS segment and unallocated corporate, and was sold to an unrelated third party for cash consideration of $60.1 million, net of costs to sell. In conjunction with the sale, we entered into a long-term operating lease for certain buildings to support RMS and unallocated corporate operations. Upon meeting the criteria for sale leaseback, we derecognized the book value of $21.6 million and recognized a pre-tax gain of approximately $38.5 million. The gain was recognized within our RMS reportable segment and unallocated corporate for $23.2 million and $15.3 million, respectively, and is included in Selling, general and administrative expenses for the nine months ended September 26, 2026 within the unaudited condensed consolidated statements of income.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Results of Operations

Consolidated Results of Operations and Liquidity

Revenue for the three months ended September 26, 2026 decreased $22.1 million, or 2.2%, to $982.7 million compared to $1,004.9 million in the corresponding period in 2025. Revenue for the nine months ended September 26, 2026 decreased $38.5 million, or 1.3%, to $2,982.6 million compared to $3,021.2 million in the corresponding period in 2025. The decrease in revenue for both the three and nine months ended September 26, 2026 was primarily due to a decrease in Manufacturing and RMS revenue due to the CDMO and Cell Solutions Divestiture and DSA revenue driven by the European Discovery Divestiture, compared to the corresponding period in 2025.

For the three months ended September 26, 2026, our operating income and operating income as a percentage of revenue were $202.6 million and 20.6% respectively, compared to $133.8 million and 13.3% respectively, in the corresponding period of 2025. For the nine months ended September 26, 2026, our operating income and operating income as a percentage of revenue were $442.4 million and 14.8% respectively, compared to $308.6 million and 10.2% respectively, in the corresponding period of 2025. The increases in operating income and operating income as a percentage of revenue for the three and nine months ended September 26, 2026 were primarily driven by the benefit from the divestiture of the CDMO business, the gain on sale of certain assets at our Wilmington, Massachusetts site in the first quarter of 2026, lower accelerated amortization expense, certain third-party legal costs incurred in fiscal year 2025, and a non-income tax benefit resulting from changes in tax law enacted and completion of certain tax requirements in a foreign jurisdiction; partially offset by the decrease in revenue described above and higher acquisition, integration and divestiture costs, when compared to the corresponding period in 2025.

Net income attributable to Charles River Laboratories International, Inc., common shareholders increased to $333.1 million in the three months ended September 26, 2026, from $54.4 million in the corresponding period of 2025. Net income to Charles River Laboratories International, Inc., common shareholders increased to $316.7 million in the nine months ended September 26, 2026, from $132.2 million in the corresponding period of 2025. The increase of $278.6 million for the three months ended September 26, 2026 was due principally to the enactment of tax legislation and completion of certain tax requirements in a foreign jurisdiction resulting in a benefit due to the reversal of an unrecognized tax benefit reserve and the increase in operating income described above, compared to the corresponding period in 2025. The increase of $184.5 million for the nine months ended September 26, 2026 was due principally to the tax benefit and the increase in operating income described above; partially offset by the CDMO and Cell Solutions Divestiture loss of $181.7 million recognized in the first half of 2026, compared to the corresponding period in 2025.

During the nine months ended September 26, 2026, our cash flows from operations were $474.9 million compared with $590.1 million for the same period in 2025. The decrease was primarily related to higher payments of variable compensation, specifically annual incentive based bonuses paid during the first quarter, as well as higher professional services fees for enterprise-wide efficiency initiatives and acquisition, integration and divestiture-related activities.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Three Months Ended September 26, 2026 Compared to the Three Months Ended September 27, 2025

Revenue and Operating Income

The following tables present consolidated revenue by type and by reportable segment:

Three Months Ended
September 26, 2026September 27, 2025$ change% change
(in thousands, except percentages)
Service revenue$780,341$808,042$(27,701)(3.4)%
Product revenue202,391196,8105,5812.8%
Total revenue$982,732$1,004,852$(22,120)(2.2)%
Three Months Ended
September 26, 2026September 27, 2025$ change% changeImpact of FX
(in thousands, except percentages)
DSA$596,322$600,685$(4,363)(0.7)%(0.2)%
Manufacturing178,878190,693(11,815)(6.2)%(0.2)%
RMS207,532213,474(5,942)(2.8)%0.7%
Total revenue$982,732$1,004,852$(22,120)(2.2)%—%

The following table presents operating income by reportable segment:

Three Months Ended
September 26, 2026September 27, 2025$ change% changeImpact of FX
(in thousands, except percentages)
DSA$172,376$123,153$49,22340.0%0.4%
Manufacturing63,83539,92623,90959.9%(0.4)%
RMS41,24034,5536,68719.4%1.9%
Unallocated corporate(74,813)(63,833)(10,980)17.2%(0.2)%
Total operating income$202,638$133,799$68,83951.4%0.7%
Operating income % of revenue20.6%13.3%730 bps

The following presents and discusses our consolidated financial results by each of our reportable segments:

DSA

Three Months Ended
September 26, 2026September 27, 2025$ change% changeImpact of FX
(in thousands, except percentages)
Revenue$596,322$600,685$(4,363)(0.7)%(0.2)%
Cost of revenue (excluding amortization of intangible assets)406,987408,112(1,125)(0.3)%
Selling, general and administrative7,33756,266(48,929)(87.0)%
Amortization of intangible assets9,62213,154(3,532)(26.9)%
Operating income$172,376$123,153$49,22340.0%0.4%
Operating income % of revenue28.9%20.5%840 bps

DSA revenue decreased $4.4 million due primarily to the sale of certain European Discovery Services businesses of $36.4 million and the effect of changes in foreign currency exchange rates of $1.5 million; partially offset by higher revenue for regulated safety assessment services of $33.5 million compared to the corresponding period in 2025.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

DSA operating income increased $49.2 million during the three months ended September 26, 2026 compared to the corresponding period in 2025. DSA operating income as a percentage of revenue for the three months ended September 26, 2026 was 28.9%, an increase of 840 bps from 20.5% for the corresponding period in 2025. Operating income and operating income as a percentage of revenue increased primarily due to a non-income tax benefit resulting from changes in tax law enacted and completion of certain tax requirements in a foreign jurisdiction and the decrease in amortization of intangible assets related to the European Discovery Divestiture.

Manufacturing

Three Months Ended
September 26, 2026September 27, 2025$ change% changeImpact of FX
(in thousands, except percentages)
Revenue$178,878$190,693$(11,815)(6.2)%(0.2)%
Cost of revenue (excluding amortization of intangible assets)79,303109,944(30,641)(27.9)%
Selling, general and administrative33,59432,5561,0383.2%
Amortization of intangible assets2,1468,267(6,121)(74.0)%
Operating income$63,835$39,926$23,90959.9%(0.4)%
Operating income % of revenue35.7%20.9%1,480 bps

Manufacturing revenue decreased $11.8 million primarily due to the sale of the CDMO business of $25.3 million; partially offset by increased revenue in our Microbial Solutions business of $7.2 million, driven primarily by higher demand for endotoxin testing reagents, and higher revenue in the Biologics Testing business of $6.6 million, compared to the corresponding period in 2025.

Manufacturing operating income increased $23.9 million during the three months ended September 26, 2026 compared to the corresponding period in 2025. Manufacturing operating income as a percentage of revenue for the three months ended September 26, 2026 was 35.7%, an increase of 1,480 bps from 20.9% for the corresponding period in 2025. Operating income and operating income as a percentage of revenue increased primarily due to the benefit from the divestiture of the CDMO business.

RMS

Three Months Ended
September 26, 2026September 27, 2025$ change% changeImpact of FX
(in thousands, except percentages)
Revenue$207,532$213,474$(5,942)(2.8)%0.7%
Cost of revenue (excluding amortization of intangible assets)138,572148,004(9,432)(6.4)%
Selling, general and administrative24,84724,934(87)(0.3)%
Amortization of intangible assets2,8735,983(3,110)(52.0)%
Operating income$41,240$34,553$6,68719.4%1.9%
Operating income % of revenue19.9%16.2%370 bps

RMS revenue decreased $5.9 million primarily driven by the divestiture of the Cell Solutions business of $6.0 million, a decrease in large research model revenue of $4.4 million, and small research model product revenue in North America of $3.8 million; partially offset by increases in small research model product revenue in China of $4.9 million, IS service revenue of $2.8 million, and the effect of changes in foreign currency exchange rates compared to the corresponding period in 2025.

RMS operating income increased $6.7 million compared to the corresponding period in 2025. RMS operating income as a percentage of revenue for the three months ended September 26, 2026 was 19.9%, an increase of 370 bps from 16.2% for the corresponding period in 2025. Operating income and operating income as a percentage of revenue increased primarily due to a decrease in amortization of intangible assets related to the sale of the Cell Solutions business; partially offset with a decrease in revenue described above, compared to the corresponding period in 2025.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Unallocated Corporate

Three Months Ended
September 26, 2026September 27, 2025$ change% changeImpact of FX
(in thousands, except percentages)
Unallocated corporate$74,813$63,833$10,98017.2%(0.2)%
Unallocated corporate % of revenue7.6%6.4%120 bps

Unallocated corporate costs consist of selling, general and administrative expenses that are not directly related or allocated to the reportable segments. The increase in unallocated corporate costs of $11.0 million, or 17.2%, compared to the corresponding period in 2025 is primarily due to higher professional services fees related to enterprise-wide efficiency initiatives and higher legal costs. Costs as a percentage of revenue for the three months ended September 26, 2026 was 7.6%, an increase of 120 bps from 6.4% for the corresponding period in 2025.

Other Income (Expense)

Three Months Ended
September 26, 2026September 27, 2025$ change% change
(in thousands, except percentages)
Other income (expense):
Interest income$958$1,422$(464)(32.6)%
Interest expense(28,525)(25,403)(3,122)12.3%
Other expense, net(4,414)(22,618)18,204(80.5)%
Total other expense, net$(31,981)$(46,599)$14,618(31.4)%

Interest expense for the three months ended September 26, 2026 was $28.5 million, an increase of $3.1 million, or 12.3%, compared to $25.4 million in the corresponding period in 2025 primarily due to higher average debt balances and non-cash interest expense recognized from the accretion of deferred purchase consideration associated with the Cambodian NHP Supplier acquisition.

Other expense, net for the three months ended September 26, 2026 was $4.4 million compared to $22.6 million for the corresponding period in 2025 primarily due to $2.2 million of venture capital and strategic equity investment net losses in 2026 compared to $20.2 million of net losses in 2025.

Income Taxes

Three Months Ended
September 26, 2026September 27, 2025$ change% change
(in thousands, except percentages)
Income before income taxes$170,657$87,200$83,45795.7%
Provision (benefit) for income taxes$(163,787)$31,644$(195,431)(617.6)%
Effective tax rate(96.0)%36.3%(13,230) bps

Income tax benefit for the three months ended September 26, 2026 was $163.8 million, compared to income tax expense of $31.6 million for the corresponding period in 2025. Our effective tax rate was (96.0)% for the three months ended September 26, 2026 compared to 36.3% for the corresponding period in 2025. The difference in our effective tax rate in the three months ended September 26, 2026 compared to the corresponding period in 2025 was primarily attributable to a $201 million tax benefit resulting from the reversal of an unrecognized tax benefit reserve due to tax legislation and completion of certain tax requirements in a foreign jurisdiction which was enacted in the third quarter of 2026, subsequent to the related acquisition.

Nine Months Ended September 26, 2026 Compared to Nine Months Ended September 27, 2025

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Revenue and Operating Income

The following tables present consolidated revenue by type and by reportable segment:

Nine Months Ended
September 26, 2026September 27, 2025$ change% change
(in thousands, except percentages)
Service revenue$2,386,780$2,446,801$(60,021)(2.5)%
Product revenue595,860574,35421,5063.7%
Total revenue$2,982,640$3,021,155$(38,515)(1.3)%
Nine Months Ended
September 26, 2026September 27, 2025$ change% changeImpact of FX
(in thousands, except percentages)
DSA$1,799,752$1,811,323$(11,571)(0.6)%0.8%
Manufacturing557,514570,014(12,500)(2.2)%1.5%
RMS625,374639,818(14,444)(2.3)%1.8%
Total revenue$2,982,640$3,021,155$(38,515)(1.3)%1.1%

The following table presents operating income by reportable segment:

Nine Months Ended
September 26, 2026September 27, 2025$ change% change**(1)**Impact of FX**(1)**
(in thousands, except percentages)
DSA$400,650$339,886$60,76417.9%(0.6)%
Manufacturing176,28043,367132,913306.5%6.9%
RMS127,290113,94413,34611.7%4.8%
Unallocated corporate(261,797)(188,595)(73,202)38.8%0.4%
Total operating income$442,423$308,602$133,82143.4%1.8%
Operating income % of revenue14.8%10.2%460 bps

The following presents and discusses our consolidated financial results by each of our reportable segments:

DSA

Nine Months Ended
September 26, 2026September 27, 2025$ change% changeImpact of FX
(in thousands, except percentages)
Revenue$1,799,752$1,811,323$(11,571)(0.6)%0.8%
Cost of revenue (excluding amortization of intangible assets)1,254,4871,250,1624,3250.3%
Selling, general and administrative114,976181,829(66,853)(36.8)%
Amortization of intangible assets29,63939,446(9,807)(24.9)%
Operating income$400,650$339,886$60,76417.9%(0.6)%
Operating income % of revenue22.3%18.8%350 bps

DSA revenue decreased $11.6 million primarily due to the sale of certain European Discovery Services businesses of $58.8 million; partially offset by higher revenue for regulated safety assessment services of $33.0 million and the effect of changes in foreign currency exchange rates of $14.3 million, compared to the corresponding period in 2025.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

DSA operating income increased $60.8 million during the nine months ended September 26, 2026 compared to the corresponding period in 2025. DSA operating income as a percentage of revenue for the nine months ended September 26, 2026 was 22.3%, an increase of 350 bps from 18.8% for the corresponding period in 2025. Operating income and operating income as a percentage of revenue increased primarily due to a non-income tax benefit resulting from changes in tax law enacted and completion of certain tax requirements in a foreign jurisdiction, the decrease in amortization of intangible assets related to the European Discovery Divestiture, lower third-party legal costs associated with the investigations by the U.S. government into the NHP supply chain, and lower restructuring activities, including asset impairments recognized within Cost of revenue; partially offset with the decrease in revenue described above, compared to the corresponding period in 2025.

Manufacturing

Nine Months Ended
September 26, 2026September 27, 2025$ change% change**(1)**Impact of FX**(1)**
(in thousands, except percentages)
Revenue$557,514$570,014$(12,500)(2.2)%1.5%
Cost of revenue (excluding amortization of intangible assets)275,885326,967(51,082)(15.6)%
Selling, general and administrative99,19799,0041930.2%
Amortization of intangible assets6,152100,676(94,524)(93.9)%
Operating income (loss)$176,280$43,367$132,913306.5%6.9%
Operating income (loss) % of revenue31.6%7.6%2,400 bps

Manufacturing revenue decreased $12.5 million primarily due to the sale of the CDMO business of $55.1 million; partially offset by increased revenue in our Microbial Solutions business of $24.7 million driven primarily by higher demand for endotoxin testing reagents, and higher revenue in the Biologics Testings business of $9.1 million, and the effect of changes in foreign currency exchange rates of $8.8 million, compared to the corresponding period in 2025.

Manufacturing operating income increased $132.9 million during the nine months ended September 26, 2026 compared to the corresponding period in 2025. Manufacturing operating income as a percentage of revenue for the nine months ended September 26, 2026 was 31.6%, an increase of 2,400 bps from 7.6% for the corresponding period in 2025. Operating income and operating income as a percentage of revenue increased primarily due to the benefit from the divestiture of the CDMO business.

RMS

Nine Months Ended
September 26, 2026September 27, 2025$ change% changeImpact of FX
(in thousands, except percentages)
Revenue$625,374$639,818$(14,444)(2.3)%1.8%
Cost of revenue (excluding amortization of intangible assets)436,360430,4355,9251.4%
Selling, general and administrative52,94077,509(24,569)(31.7)%
Amortization of intangible assets8,78417,930(9,146)(51.0)%
Operating income$127,290$113,944$13,34611.7%4.8%
Operating income % of revenue20.4%17.8%260 bps

RMS revenue decreased $14.4 million primarily driven by the divestiture of the Cell Solutions business of $12.2 million as well as a decrease in GEMS and RADS service revenue of $6.0 million, large research model product revenue of $8.7 million, and small research model product revenue in North America of $13.7 million; partially offset by an increase in small research model product revenue in China of $11.3 million, IS service revenue of $3.7 million, and the effect of changes in foreign currency exchange rates of $12 million compared to the corresponding period in 2025.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

RMS operating income increased $13.3 million compared to the corresponding period in 2025. RMS operating income as a percentage of revenue for the nine months ended September 26, 2026 was 20.4%, an increase of 260 bps from 17.8% for the corresponding period in 2025. Operating income and operating income as a percentage of revenue increased primarily due to lower site consolidation charges and the gain on sale of certain assets at our Wilmington, Massachusetts site recognized within Selling, general and administrative expenses and a decrease in amortization of intangible assets related to the sale of the Cell Solutions business; partially offset by an increase in asset impairments recognized within Cost of revenue and the lower revenue described above, compared to the corresponding period in 2025.

Unallocated Corporate

Nine Months Ended
September 26, 2026September 27, 2025$ change% changeImpact of FX
(in thousands, except percentages)
Unallocated corporate$261,797$188,595$73,20238.8%0.4%
Unallocated corporate % of revenue8.8%6.2%260 bps

Unallocated corporate costs consist of selling, general and administrative expenses that are not directly related or allocated to the reportable segments. The increase in unallocated corporate costs of $73.2 million, or 38.8%, compared to the corresponding period in 2025 is primarily due to higher acquisition, integration and divestiture costs primarily associated with our previously discussed activities and higher professional services fees related to enterprise-wide efficiency initiatives; partially offset by the $15.3 million gain on sale of certain assets at our Wilmington, Massachusetts site. Costs as a percentage of revenue for the nine months ended September 26, 2026 were 8.8%, an increase of 260 bps from 6.2% for the corresponding period in 2025.

Other Income (Expense)

Nine Months Ended
September 26, 2026September 27, 2025$ change% change
(in thousands, except percentages)
Other income (expense):
Interest income$3,023$3,923$(900)(22.9)%
Interest expense(85,607)(83,254)(2,353)2.8%
Other expense, net(165,954)(34,675)(131,279)378.6%
Total other expense, net$(248,538)$(114,006)$(134,532)118.0%

Interest expense for the nine months ended September 26, 2026 was $85.6 million, an increase of $2.4 million, or 2.8%, compared to $83.3 million in the corresponding period in 2025 primarily due to non-cash interest expense recognized from the accretion of deferred purchase consideration associated with the Cambodian NHP Supplier acquisition.

Other expense, net for the nine months ended September 26, 2026 was $166.0 million compared to $34.7 million for the corresponding period in 2025 due principally to the loss of $181.7 million in connection with the CDMO and Cell Solutions Divestiture; partially offset by a $15.5 million gain in the fair value of life insurance policies in 2026 compared to a $6.6 million gain in 2025, as well as $4.6 million of venture capital and strategic equity investment net gains in 2026 compared to $31.6 million of venture capital and strategic equity investment net losses in 2025.

Income Taxes

Nine Months Ended
September 26, 2026September 27, 2025$ change% change
(in thousands, except percentages)
Income before income taxes$193,885$194,596$(711)(0.4)%
Provision (benefit) for income taxes$(124,997)$60,469$(185,466)(306.7)%
Effective tax rate(64.5)%31.1%(9,560) bps

Income tax benefit for the nine months ended September 26, 2026 was $125.0 million, compared to income tax expense of $60.5 million for the corresponding period in 2025. Our effective tax rate was (64.5)% for the nine months ended September 26, 2026 compared to 31.1% for the corresponding period in 2025. The difference in our effective tax rate in the nine months ended September 26, 2026 compared to the corresponding period in 2025 was primarily attributable to a $201 million tax

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

benefit resulting from the reversal of an unrecognized tax benefit reserve following the enactment of tax legislation and completion of certain tax requirements in a foreign jurisdiction.

Liquidity and Capital Resources

Liquidity and Cash Flows

In general, we require cash to fund our working capital needs, capital expansion, acquisitions, debt payments, lease payments, venture capital and strategic equity investments, restructuring initiatives, and pension obligations. Our principal sources of liquidity have been our cash flows from operations supplemented by long-term borrowings. Based on our current business plan, we believe that our existing funds, when combined with cash generated from operations and our access to financing resources, are sufficient to fund our operations for the foreseeable future.

The following table presents our cash, cash equivalents and short-term investments:

September 26, 2026December 27, 2025
(in thousands)
Cash and cash equivalents:
Held in U.S. entities$4,537$4,514
Held in non-U.S. entities195,844209,256
Total cash and cash equivalents$200,381$213,770

The following table presents our net cash provided by operating activities:

Nine Months Ended
September 26, 2026September 27, 2025
(in thousands)
Net income$318,882$134,127
Adjustments to reconcile net income to net cash provided by operating activities182,131448,690
Changes in assets and liabilities(26,126)7,309
Net cash provided by operating activities$474,887$590,126

Net cash provided by operating activities represents the cash receipts and disbursements related to all of our activities other than investing and financing activities. Operating cash flow is derived by adjusting our net income for (1) non-cash operating items such as depreciation and amortization, stock-based compensation, goodwill impairment, debt financing costs, deferred income taxes, write downs of inventories, provisions of credit losses, long-lived asset impairment changes, gains and/or losses on venture capital and strategic equity investments, gains and/or losses on divestitures, and changes in fair value of contingent consideration, as well as (2) changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our results of operations.

During the nine months ended September 26, 2026, our cash flows from operations were $474.9 million compared with $590.1 million for the same period in 2025. The decrease was primarily related to higher payments of variable compensation, specifically annual incentive based bonuses paid during the first quarter, as well as higher professional services fees for enterprise-wide efficiency initiatives and acquisition, integration and divestiture-related activities.

The following table presents our net cash used in investing activities:

Nine Months Ended
September 26, 2026September 27, 2025
(in thousands)
Acquisition of businesses and assets, net of cash acquired$(467,254)$—
Capital expenditures(133,823)(130,202)
Investments, net4,158(6,907)
Proceeds from surrender of life insurance policies58,127—
Proceeds from sale of businesses and assets, net176,56317,441
Other, net(7,292)3,154
Net cash used in investing activities$(369,521)$(116,514)

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Investing activities primarily consist of cash used to fund capital expenditures to support the growth of our business, purchases and sales of investments related to our venture capital and strategic equity investment portfolios, and asset and business acquisitions, periodically offset by cash from divestitures.

For the nine months ended September 26, 2026, cash used in investing activities was primarily driven by the acquisition of the Cambodian NHP Supplier and PathoQuest coupled with capital expenditures; partially offset by proceeds from the sale of the European Discovery Services businesses, the sale of certain assets at our Wilmington, Massachusetts site and the surrender of certain Company-owned life insurance policies.

For the nine months ended September 27, 2025, cash used in investing activities was primarily driven by capital expenditures; partially offset by proceeds from divestitures of certain site and business assets.

The following table presents our net cash used in financing activities:

Nine Months Ended
September 26, 2026September 27, 2025
(in thousands)
Proceeds from long-term debt and revolving credit facility$1,420,223$1,070,861
Payments on long-term debt, revolving credit facility, and finance lease obligations(1,081,266)(1,141,500)
Proceeds from exercises of stock options29,7333
Purchase of treasury stock(324,105)(360,577)
Payment of contingent consideration and deferred consideration for acquisitions(111,394)(21,822)
Purchase of remaining equity interest of other redeemable noncontrolling interest—(19,140)
Other, net(4,274)(12,687)
Net cash used in financing activities$(71,083)$(484,862)

Financing activities primarily consist of the proceeds and repayments of debt and certain equity related transactions including treasury stock purchases and employee stock option exercises.

For the nine months ended September 26, 2026, net cash used in financing activities was primarily driven by the following activity:

  • Net proceeds of $339.0 million, primarily from our Credit Facility

  • Treasury stock purchases of $300.0 million associated with our stock repurchase program and $20.8 million due to the netting of common stock upon vesting of stock-based awards in order to satisfy individual statutory tax withholding requirements, along with related excise tax payments

  • Payment of $100.0 million associated with deferred payments related to the acquisition of the Cambodian NHP Supplier made during the three months ended September 26, 2026

  • Payment of $11.4 million associated with contingent consideration related to the acquisition of Noveprim

For the nine months ended September 27, 2025, net cash used in financing activities was primarily driven by the following activity:

  • Net payments of $70.6 million, of which $60.5 million was from our Credit Facility

  • Treasury stock purchases of $350.0 million associated with our stock repurchase program and $9.9 million due to the netting of common stock upon vesting of stock-based awards in order to satisfy individual statutory tax withholding requirements

  • Payment of $21.8 million associated with contingent consideration related to the acquisition of Noveprim

  • Payment of $19.1 million for the remaining 8% equity interest in another redeemable noncontrolling interest

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Financing and Market Risk

We are exposed to market risk from changes in interest rates and currency exchange rates, which could affect our future results of operations and financial condition. We manage our exposure to these risks through our regular operating and financing activities.

Amounts outstanding under our Credit Facility and our Senior Notes were as follows:

September 26, 2026December 27, 2025
(in thousands)
Revolving facility$943,174$616,503
4.25% Senior Notes due 2028500,000500,000
3.75% Senior Notes due 2029500,000500,000
4.00% Senior Notes due 2031500,000500,000
Total$2,443,174$2,116,503

The Credit Facility provides for up to $2.0 billion of multi-currency revolving credit and has a maturity date of December 2029, with no required scheduled payment before that date. The interest rates applicable to the revolving facility are equal to (A) for revolving loans denominated in U.S. dollars, at our option, either the base rate (which is the higher of (1) the prime rate, (2) the federal funds rate plus 0.50%, or (3) the one-month adjusted SOFR rate plus 1.0%) or the adjusted SOFR rate, (B) for revolving loans denominated in euros, the adjusted EURIBOR rate and (C) for revolving loans denominated in sterling, the daily simple SONIA rate, in each case, plus an interest rate margin based upon our leverage ratio.

Our off-balance sheet commitments related to our outstanding letters of credit as of September 26, 2026 and December 27, 2025 were $21.7 million and $22.0 million, respectively.

Foreign Currency Exchange Rate Risk

We operate on a global basis and have exposure to foreign currency exchange rate fluctuations for our financial position, results of operations, and cash flows.

While the financial results of our global activities are reported in U.S. dollars, our foreign subsidiaries typically conduct their operations in their respective local currency. The principal functional currencies of our foreign subsidiaries are the Euro, Canadian Dollar, and British Pound. During the nine months ended September 26, 2026, the most significant drivers of foreign currency translation adjustment we recorded as part of Other comprehensive income (loss) were the British Pound, Canadian Dollar, Mauritian Rupee, Euro, Chinese Yuan, and Hungarian Forint.

Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our financial position, results of operations, and cash flows. As the U.S. dollar strengthens against other currencies, the value of our non-U.S. revenue, expenses, assets, liabilities, and cash flows will generally decline when reported in U.S. dollars. The impact to net income (loss) as a result of a U.S. dollar strengthening will be partially mitigated by the value of non-U.S. expenses, which will decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenue, expenses, assets, liabilities, and cash flows will generally increase when reported in U.S. dollars. For the nine months ended September 26, 2026, our revenue would have decreased by $135.8 million, and our operating income would have decreased by $33.2 million, if the U.S. dollar exchange rate had strengthened by 10%, with all other variables held constant.

We attempt to minimize this exposure by using certain financial instruments in accordance with our overall risk management and our hedge policy. We do not enter into speculative derivative agreements.

Repurchases of Common Stock

On October 29, 2025, our Board of Directors approved a stock repurchase program of $1.0 billion. During the nine months ended September 26, 2026, we repurchased 1.7 million shares of common stock for $300.0 million under the stock repurchase program. As of September 26, 2026, we had $700.0 million remaining on the authorized $1.0 billion stock repurchase program.

Additionally, our stock-based compensation plans permit the netting of common stock upon vesting of restricted stock, restricted stock units, and performance share units in order to satisfy individual statutory tax withholding requirements. During the nine months ended September 26, 2026, we acquired 0.1 million shares for $20.8 million through such netting.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements prepared in accordance with generally accepted accounting principles in the U.S. The preparation of these financial statements requires us to make certain estimates and assumptions that may affect the reported amounts of assets and liabilities, the reported amounts of revenues and expenses during the reported periods, and the related disclosures. These estimates and

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

assumptions are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on our historical experience, trends in the industry, and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from our estimates under different assumptions or conditions.

We believe that the application of our accounting policies, each of which require significant judgments and estimates on the part of management, are the most critical to aid in fully understanding and evaluating our reported financial results. Our significant accounting policies are more fully described in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report on Form 10-K for fiscal year 2025 as filed with the SEC on February 18, 2026. There have been no changes in our critical accounting policies during the nine months ended September 26, 2026.

Recent Accounting Pronouncements

For a discussion of recent accounting pronouncements please refer to Note 1, “Basis of Presentation,” in this Quarterly Report on Form 10-Q. Other than as discussed in Note 1, “Basis of Presentation,” we did not adopt any other new accounting pronouncements during the nine months ended September 26, 2026 that had a significant effect on our unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

Previous: Item 1. Financial Statements · Next: Item 3. Quantitative and Qualitative Disclosures about Market Risk